Welcome to our dedicated page for Inmode Ltd. news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode Ltd. stock.
News about InMode Ltd. (INMD) centers on its role as a global provider of medical technologies based on novel radio frequency (RF) energy, along with its financial performance as a Nasdaq-listed company. Press releases regularly highlight quarterly and annual results, revenue guidance ranges, and commentary from management on market conditions, tariffs, and geopolitical developments affecting its operating environment.
Investors following InMode news will find detailed updates on quarterly revenues, gross margins, operating income, and cash position, often presented alongside non-GAAP metrics that exclude share-based compensation and related tax adjustments. The company also issues announcements when it provides or revises full-year revenue guidance, giving insight into management’s expectations for its RF-based aesthetic and medical device business.
Another key news theme is capital markets and investor relations activity. InMode frequently announces participation in major healthcare and medical technology investor conferences hosted by firms such as UBS, Jefferies, Canaccord Genuity, Baird, and Needham. These items describe fireside chats, formal presentations, and one-on-one investor meetings featuring senior executives, as well as links to live webcasts and replays.
Corporate governance and shareholder matters also appear in the news flow. For example, an external stockholder, DOMA Perpetual Capital Management LLC, publicly released a letter urging InMode’s board to expand capital returns to shareholders, focusing on share repurchases and discussing the company’s cash position and valuation. In addition, InMode has announced leadership changes, such as the appointment of a President of North America, reflecting developments in its organizational structure and regional strategy.
By tracking INMD news, readers can monitor earnings releases, guidance updates, conference participation, shareholder communications, and leadership announcements that together provide a current picture of how InMode presents its business and responds to financial and market dynamics.
InMode Ltd. (Nasdaq: INMD) announced that its leadership team, including Moshe Mizrahy (CEO), Yair Malca (CFO), and Spero Theodorou (CMO), will present at the 25th Annual Needham Growth Conference on Jan. 12, 2023. The event, moderated by Mike Matson, starts at 10:15 am Eastern Time and will be accessible via webcast on InMode's Investor Relations website. Additionally, InMode will conduct in-person meetings on Jan. 11 and virtual meetings on Jan. 12.
InMode Ltd. (Nasdaq: INMD), a global leader in medical technologies, announced participation in three major investor conferences in November and December 2022. The events include:
- Jefferies London Healthcare Conference: Presentation on November 15 at 10:20 a.m. GMT
- Canaccord Genuity MTDF Conference: Presentation on November 17 at 1:00 p.m. ET
- Cantor Medical & Aesthetic Dermatology Conference: Panel on December 8 at 1:45 p.m. ET
Live webcasts will be available for each presentation. For more details, visit InMode's website.
InMode Ltd. (Nasdaq: INMD) reported a record-breaking revenue of $121.2 million for Q3 2022, marking a 29% increase compared to Q3 2021. The company achieved a GAAP net income of $48.8 million or $0.58 per diluted share, up from $44.7 million or $0.52 in the previous year. Non-GAAP net income reached $56.6 million with a non-GAAP EPS of $0.66. Significant growth was seen in consumables and services, increasing 53% year-over-year to $13.9 million. Management also increased revenue targets for the EmpowerRF platform and plans global expansion.
InMode Ltd. (Nasdaq: INMD) anticipates record third-quarter revenue between $120.5 million and $120.9 million, alongside a projected non-GAAP gross margin of 84% to 85% and earnings per diluted share ranging from $0.64 to $0.65. The company has also raised its full-year 2022 revenue guidance to between $445 million and $450 million. A conference call to discuss these results is scheduled for October 27, 2022, at 8:30 a.m. ET.
On September 29, 2022, InMode Ltd. (Nasdaq: INMD) announced actress Eva Longoria as its Global Brand Ambassador. Longoria, known for her work on Desperate Housewives and her philanthropic efforts, will promote InMode's innovative medical technologies. She has personally utilized InMode’s EvolveX Transform and Morpheus8 Body treatments to address post-pregnancy body changes, emphasizing their effectiveness. InMode develops and markets cutting-edge devices leveraging radiofrequency technology across multiple medical fields, striving to enhance surgical procedures and existing treatments.
InMode Ltd. (Nasdaq: INMD) announced that CFO Yair Malca will present at the Baird 2022 Global Healthcare Conference on Sept. 13, 2022, at 1:25 pm Eastern Time at the InterContinental New York Barclay hotel. The presentation will be webcast on InMode's Investor Relations website. Malca will also hold one-on-one investor meetings on Sept. 13 and Sept. 14. InMode specializes in innovative medical technologies, focusing on minimally invasive RF technologies applicable in various medical fields.
InMode Ltd. (NASDAQ: INMD), a leader in innovative medical technologies, announced participation in the 7th Annual Needham Virtual Med Tech & Diagnostics Conference on August 16, 2022. Senior management, including Chairman and CEO Moshe Mizrahy and CFO Yair Malca, will engage in one-on-one meetings with investors that day. Interested parties can schedule meetings via their Needham representatives. InMode develops cutting-edge devices using radiofrequency technology for various medical fields, emphasizing minimally invasive surgical solutions.
InMode Ltd. (Nasdaq: INMD) reported record revenues of $113.5 million for Q2 2022, marking a 30% increase year-over-year. The company's GAAP net income rose to $44.0 million, with earnings per diluted share at $0.52. Non-GAAP net income reached $50.4 million, translating to $0.59 per diluted share. The company expects 2022 revenues of $425 million to $435 million and a non-GAAP gross margin between 83% and 85%. InMode also received Health Canada's endorsement for its EmpowerRF platform.
InMode Ltd. (NASDAQ: INMD) announced that CFO Yair Malca will present at the Canaccord 42nd Annual Growth Conference on August 11, 2022, at 3:30 PM ET, in Boston. The presentation will be available via webcast on the company's Investor Relations website. Malca is also scheduled for one-on-one meetings with investors on August 10 and August 11. InMode specializes in innovative medical technologies, focusing on minimally invasive RF procedures in various medical fields.
InMode Ltd. (INMD) announced expectations for record financial results in Q2 2022, forecasting revenue between $113.0 million to $113.3 million. The company anticipates a non-GAAP earnings per diluted share of $0.57 to $0.58. Additionally, InMode raised its full-year revenue guidance to a range of $425 million to $435 million, up from a previous range of $415 million to $425 million. The company attributes this growth to strong demand for its medical technologies in aesthetic surgery.